Poxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770 Jul 5, 2022
Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting Jun 22, 2022
Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041 Jun 9, 2022
Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy May 17, 2022
Poxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy Apr 11, 2022
